OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 60
- Registration Number
- NCT05848700
- Locations
- πΊπΈ
Woodland International Research Group, LLC, Little Rock, Arkansas, United States
πΊπΈWoodland Research Northwest, Rogers, Arkansas, United States
πΊπΈBehavioral Clinical Research, Inc, Miami Lakes, Florida, United States
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2025-04-11
- Target Recruit Count
- 434
- Registration Number
- NCT05729373
- Locations
- πΊπΈ
University of Alabama at Birmingham, Huntsville, Alabama, United States
πΊπΈIMA Clinical Research Phoenix, Phoenix, Arizona, United States
πΊπΈProScience Research Group, Culver City, California, United States
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2025-04-10
- Target Recruit Count
- 101
- Registration Number
- NCT05628103
- Locations
- πΊπΈ
Advanced Research Center, Inc., Anaheim, California, United States
πΊπΈClinical Innovations Inc., Bellflower, California, United States
πΊπΈProScience Research Group, Culver City, California, United States
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2025-04-15
- Target Recruit Count
- 1030
- Registration Number
- NCT05593029
- Locations
- πΊπΈ
For additional information regarding sites, contact 844-687-8522, New York, New York, United States
A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- Drug: Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 19
- Registration Number
- NCT05542264
- Locations
- πΊπΈ
Woodland International Research Group, Little Rock, Arkansas, United States
πΊπΈShari DeSilva, Rogers, Arkansas, United States
πΊπΈMidwest Clinical Research Center, Dayton, Ohio, United States
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2025-05-30
- Target Recruit Count
- 337
- Registration Number
- NCT05536414
- Locations
- πΊπΈ
Yuma CNS Research, Yuma, Arizona, United States
πΊπΈSanRo Clinical Research Group LLC, Bryant, Arkansas, United States
πΊπΈBehavioral Research Specialists-California-Irvine, Glendale, California, United States
Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety
A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 15
- Registration Number
- NCT05463770
- Locations
- πΊπΈ
Woodland International Research Group, LLC, Little Rock, Arkansas, United States
πΊπΈWoodland Research Northwest, LLC, Rogers, Arkansas, United States
πΊπΈCollaborative Neuroscience Research, LLC, Long Beach, California, United States
A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- Other: placebo capsule
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2025-04-04
- Target Recruit Count
- 574
- Registration Number
- NCT05428033
- Locations
- πΊπΈ
For additional information regarding sites, contact 844-687-8522, New York, New York, United States
A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard
- Conditions
- Schizophrenia
- Interventions
- Drug: Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 31
- Registration Number
- NCT05402111
- Locations
- πΊπΈ
Woodland International Research Group, Little Rock, Arkansas, United States
πΊπΈWoodland Research Northwest, LLC, Rogers, Arkansas, United States
πΊπΈCollaborative Neuroscience Research, LLC, Long Beach, California, United States